Half-Year 2022 Financial and Clinical Trials Update
Roche
2 NMEs launched in 2022: Vabysmo and Lunsumio
First-in-class bispecifics launched in ophthalmology and malignant hematology
Roche: Leading in bispecific antibodies
TECENTRIQ™
atezolizumab
VENCLEXTA
venetoclax tablets
ALECENSA
alectinib capsules
150mg
COTELLIC
LUXTURNA
voretigene neparvovec-rzyl
for ubertal injection
xofluza
(balaxavir marboxil) tablets
ENSPRYNG
POLIVY
polatumumab vedotin
|
150
ROZLYTREK
HEMLIBRA.
emicizumab-kxwh
injection for subsu
OCREVUS
ocrelizumab
PHESGO
pertuzumab/trastuzumab hyaluronidase-zz
2017
Evrysdi.
risdiplam
GAVRETO
pralsetinib
RONAPREVE
casirivimab and imdevimab
SuSvim o™
ranibizumab injection
VABYSMO
Lunsumic
2015
2016 2017 | 2018 | 2019 | 2020 2021
2022
2022
14
First bispecific mAb that bridges activated factor IX (FIXa) and
FX to restore function of missing FVIII
Approved for severe, moderate and mild hemophilia A and for
patients with inhibitors
HEMLIBRA.
emicizumab-kxwh
go
First bispecific mAb to simultaneously target VEGF-A and Ang2
to reduce neovascularization and inflammation to stabilise
vessels
Approved by FDA in nAMD and DME; RVO trials ongoing
•
VABYSMO
T cell engaging bispecific mAb that binds simultaneously to
CD20 on the surface of malignant B cells and to CD3 on the
surface of T cells, thereby activating T cell induced cancer cell
killing
•
Lunsumic
Approved by EMA in FL, DLBCL trials ongoing mosunetuzumab
NME=new molecular entity; mAb-monoclonal antibody; VEGF-Vascular endothelial growth factor; Ang-2-Angiopoietin-2; DME-diabetic macular edema; nAMD-neovascular age-related macular degeneration; DLBCL-diffuse large
B-cell lymphoma; FL-follicular lymphoma; RVO-retinal vein occlusion
12View entire presentation